Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical and Lundbeck have released a new treatment for Parkinson's disease called Azilect into the UK. The companies plan to market the product in additional European countries starting in Germany in the coming weeks.
Subscribe to our email newsletter
The once-daily treatment can be used for Parkinson’s disease (PD) both as monotherapy in patients with early PD and as an adjunct treatment in moderate to advanced disease.
The UK release represents the first launch of Azilect in Europe following the issuance of marketing authorization by the European Commission earlier this year. The marketing authorization is valid throughout Europe and additional launches are planned for the remainder of this year and for 2006.
“Azilect is an effective, simple and well tolerated drug for the treatment of both early and late-stage Parkinson’s disease”, said Ole Chrintz, Lundbeck’s executive vice president in charge of sales and marketing in Europe. “The launch of Azilect is Lundbeck’s third launch of a new, innovative drug in Europe within a period of only three years, representing an important contribution to the company’s portfolio and long-term strategy of becoming one of the world’s leading companies in the field of psychiatry and neurology.”
Azilect is a novel, potent, second-generation selective irreversible monoamine oxidase type B (MAO-B) inhibitor that blocks the breakdown of dopamine, a substance in the brain needed to facilitate movement.
The development of Azilect is part of a long-term alliance for co-development in Parkinson’s disease and European marketing between Lundbeck and Teva. In the three major European markets, the UK, Germany and France Teva and Lundbeck will co-promote Azilect.